Abstract 119P
Background
To conduct a comparative analysis of the effectiveness of hypofractional and classical radiotherapy regimens in neoadjuvant chemoradiotherapy for locally advanced rectal cancer (LARC).
Methods
This study based on a retrospective analysis of a database in patients with LARC who underwent a course of neoadjuvant chemoradiotherapy followed by surgery. The patients were divided into two groups: the first (main) group, 104 patients who underwent a course of hypofractionated chemotherapy (4 Gy x 40 Gy 3 fractions per week) in combination with capecitabine 1650 mg/m2 in two doses. The second group (control group) included 120 patients who underwent a course of CRT in the classical fractionation regimen (2 Gy x 50-58 Gy 5 fractions per week) in combination with capecitabine 1650 mg/m2 in two doses. The main evaluated indicators are the frequency of pCR and cCR. Additional assessed indicators are the severity of early radiation toxicity, the frequency of local relapses, overall and disease-free survival.
Results
The study included 224 patients. The average duration of the CRT course in the study group was 22.56 (95% CI from 21.94 to 23.18) days, in the control group - 38.84 (95% CI from 38.12 to 39.54), p=0.0001. Radiation toxicity grade III and IV was registered in 5.75% of patients in the study group and in 6.41% of patients in the control group. pCR in the study groups was achieved in 19.23% and 15.83% of cases, respectively, p=0.504. The cCR in the studied groups was achieved in 25% and 18.3% of cases, respectively, p=0.226. The median time without progression was 37.6 months. In the main and control groups, local control rates were 91.34% and 88.3% respectively, p=0.954, HR=1.05 (95% CI 0.21 to 5.22). Five-year disease-free survival in the main group was 71.1% and in the control group 60.8%, respectively, p=0.353, HR=0.79 (95% CI 0.42 to 1.35). Five-year overall survival in the main and control groups were 81.7% and 79.2%, respectively, p=0.743, HR=0.87 (95% CI 0.39 to 1.92).
Conclusions
Thus, the hypofractionation regimen showed high antitumor efficacy and can be considered as an alternative and not inferior to the classical regimen in neoadjuvant CRT in patients with LARC.
Clinical trial identification
N/A
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
73TiP - Global phase III studies evaluating vepdegestrant in estrogen receptor (ER)+/human epidermal growth factor receptor 2 (HER2)- advanced breast cancer: VERITAC-2 and VERITAC-3
Presenter: Hiroji Iwata
Session: Poster Display
Resources:
Abstract
78P - First-in-human phase I study of TT-00434, an orally available FGFR (1-3) inhibitor in patients with advanced solid tumors
Presenter: Chia Jui Yen
Session: Poster Display
Resources:
Abstract
79P - Accelerated identification of recurrent neoantigens for the development of off-the-shelf cancer vaccines
Presenter: Le Son Tran
Session: Poster Display
Resources:
Abstract
80P - Safety, preliminary efficacy, and pharmacokinetics of HLX26 plus serplulimab in advanced solid tumours: An open-label, dose-escalation phase I study
Presenter: Yanmin Wu
Session: Poster Display
Resources:
Abstract
81P - A first-in-human, multiple dose and dose escalation phase I study to investigate the safety, tolerability and antitumor activity of SmarT cells plus PD-1 blocking antibodies in patients with far advanced/metastatic solid tumors
Presenter: Qin Liu
Session: Poster Display
Resources:
Abstract
82P - NEXUS: A phase I dose escalation study of selinexor plus nivolumab and ipilimumab in Asian patients with advanced/metastatic solid malignancies
Presenter: Gloria Chan
Session: Poster Display
Resources:
Abstract
83P - The updated report of phase I trial of VG2025, a non-attenuated HSV-1 oncolytic virus expressing IL-12 and IL-15/RA payloads, in patients with advanced solid tumors
Presenter: Yinan Shen
Session: Poster Display
Resources:
Abstract
84P - T cell receptor repertoire profiles of tumor -infiltrating lymphocytes improves neoantigen prioritization for personalized cancer immunotherapy
Presenter: Tran Nguyen
Session: Poster Display
Resources:
Abstract
85P - Oligometastatic solid tumors: Disease characteristics and role of local therapies
Presenter: Alshimaa Al Hanafy
Session: Poster Display
Resources:
Abstract
86P - Efficacy and safety of HLX07 monotherapy in advanced cutaneous squamous cell carcinoma: An open-label, multicentre phase II study
Presenter: Changxing Li
Session: Poster Display
Resources:
Abstract